218 patents
Page 2 of 11
Utility
Crystalline form of a PD-1/PD-L1 inhibitor
19 Sep 23
The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Shili Chen, Mei Li, Pingli Liu, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou
Filed: 5 Nov 21
Utility
Salts of a PD-1/PD-L1 inhibitor
12 Sep 23
The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Pingli Liu, David J. Meloni, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 7 Aug 20
Utility
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
12 Sep 23
The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 17 Jun 21
Utility
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
5 Sep 23
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Stacey Shepard
Filed: 8 Mar 22
Utility
Carboxamide compounds and uses thereof
22 Aug 23
Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Wenqing Yao
Filed: 9 Sep 20
Utility
ALK2 inhibitors for the treatment of anemia
15 Aug 23
Provided herein are methods of treating anemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor.
Francis Séguy, Ekaterine Asatiani, Yaoyu Chen
Filed: 15 Jun 21
Utility
Heterocyclic compounds as immunomodulators
8 Aug 23
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 30 Dec 20
Utility
Tricyclic heterocyclic compounds as sting activators
1 Aug 23
The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
Filed: 2 Mar 21
Utility
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
18 Jul 23
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 4 Jun 21
Utility
Naphthyridinone compounds as JAK2 V617F inhibitors
4 Jul 23
The present application provides naphthyridinone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Stacey Shepard, Lixin Shao, Liangxing Wu, Wenqing Yao
Filed: 17 Jun 21
Utility
Processes of preparing a JAK1 inhibitor
27 Jun 23
The present application provides processes for preparing 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H, 1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, and phosphoric acid salt thereof, which is useful as a selective (Janus kinase 1) JAK1 inhibitor, as well as salt forms and intermediates related thereto.
Jiacheng Zhou, Yingrui Dai, Zhongjiang Jia, Yongchun Pan, James M. Parks, Anthony J. Tomaine, Jianji Wang, Aibin Zhang
Filed: 2 Jun 21
Utility
Tricyclic urea compounds as JAK2 V617F inhibitors
30 May 23
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Kai Liu, Brent Douty, Daniel Levy, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 26 Aug 21
Utility
Methods of treating cancer with an FGFR inhibitor
18 Apr 23
This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.
Tao Ji, Krishnaswamy Yeleswaram
Filed: 6 Mar 20
Utility
Biomarkers for vitiligo
11 Apr 23
Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
Filed: 18 Mar 20
Utility
Heterocyclic compounds as immunomodulators
28 Mar 23
Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
Filed: 4 May 21
Utility
Bicyclic heterocycles as FGFR inhibitors
21 Mar 23
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
Filed: 14 Oct 20
Utility
Heterocyclic compounds as immunomodulators
21 Mar 23
Zhenwu Li, Liangxing Wu, Wenqing Yao
Filed: 25 Sep 20
Utility
Topical treatment of vitiligo by a JAK inhibitor
14 Mar 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen Butler, Jim Lee, Kang Sun, Fiona Kuo, Michael Howell
Filed: 10 Jun 20
Utility
JAK1 pathway inhibitors for the treatment of gastrointestinal disease
7 Mar 23
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.
Krishnaswamy Yeleswaram, Paul Smith, Gregory F. Hollis
Filed: 19 Dec 19
Utility
PD-L1/STING conjugates and methods of use
7 Mar 23
The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
Liangxing Wu, Zhenwu Li, Wenqing Yao
Filed: 21 Nov 19